Search for a command to run...
Abstract Objective Ongoing pandemic is being tackled by many in many ways. Simple yet effective age-old formulations might hold a key in better management of the disease. Objective was to run a series of studies to make and explore one such formulation through reverse-pharmacology. Thinqure 20 is a polyherbal formulation that contains Piper longum, Piper nigrum, Zingiber officinale , and rock salt. Thinqure20 was designed to work as an antiviral drug, especially against SARS CoV-2 virus. Hence the present Clinical and subsequent non-clinical studies were carried-out to evaluate efficacy, safety and tolerability of Thinqure 20 in Covid-19 infection. Methods Clinical study was conducted to evaluate safety, efficacy and tolerability of Thinqure 20 in Covid-19 patients (CTRI/2021/03/032471). The treatment duration was 5 days. Patients were assessed for efficacy, safety, and tolerability of Thinqure20. Subsequently, non-clinical in-vitro cell line study, antiviral and antifungal, COVID SPIKE ACE2 inhibition studies were done on Thinqure20 extract. ASTM guidelines were followed for the same. Results The clinical study showed the mean percentage reduction in the viral load from baseline to end of the study visit of Thinqure 20 to be 75.4%, where the minimum reduction was 59.3%, while the maximum reduction in viral load was 100%. There were 04 clinical adverse events reported which were mild in nature. Viral load testing was done by Quantitative RT-qPCR for SARS-CoV-2 (Covid-19) RNA method from NABL accredited lab. A total of 30 patients were enrolled in the study. 29 patients completed the study. In the invitro study on cell-line, the extract showed potential antiviral activity against MS2 bacteriophage, a non-enveloped virus, influenza virus, and human coronavirus with IC90 value at > 10mg/ml. The sample also presented antifungal ability against Mucor racemosus with EC50 value at concentration 1mg/ml. Thinqure 20 was tested for its ACE2 receptor inhibitory activity. ). The kit-based SARS inhibitor showed 89.00% ACE 2 receptor inhibition when used as per KIT’s instructions. Conclusion The results showed that Thinqure 20 has potential against non-enveloped viruses and enveloped viruses including human coronavirus. It also showed antifungal activity against mucor strain. Evidences support that the use of Thinqure 20 has beneficial effects in the treatment of Covid19 which may be linked to a decrease in total viral load in patients. It provided better relief for the recovery of the COVID-19 disease.